Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Total Current Liabilities (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Total Current Liabilities for 4 consecutive years, with $60.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities fell 17.6% to $60.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $60.5 million, a 17.6% decrease, with the full-year FY2025 number at $60.5 million, down 17.6% from a year prior.
  • Total Current Liabilities was $60.5 million for Q4 2025 at Day One Biopharmaceuticals, up from $56.5 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $93.7 million in Q2 2024 to a low of $8.2 million in Q1 2022.
  • A 4-year average of $38.1 million and a median of $29.7 million in 2023 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 282.29% in 2024, then plummeted 45.34% in 2025.
  • Day One Biopharmaceuticals' Total Current Liabilities stood at $16.6 million in 2022, then skyrocketed by 77.6% to $29.5 million in 2023, then skyrocketed by 148.92% to $73.5 million in 2024, then decreased by 17.6% to $60.5 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Total Current Liabilities are $60.5 million (Q4 2025), $56.5 million (Q3 2025), and $51.2 million (Q2 2025).